Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Perfiles genómicos en pacientes con cáncer

23 de septiembre de 2026 actualizado por: Memorial Sloan Kettering Cancer Center

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Estimado)

200

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: David Solit, MD
  • Número de teléfono: 646-888-2641

Copia de seguridad de contactos de estudio

  • Nombre: Zsofia Stadler, MD
  • Número de teléfono: 646-888-4039

Ubicaciones de estudio

    • Connecticut
      • Bridgeport, Connecticut, Estados Unidos, 06606
        • Aún no reclutando
        • St. Vincent (Data Collection Only)
        • Contacto:
          • Christopher Iannuzzi, MD
          • Número de teléfono: 203-576-6000
      • Hartford, Connecticut, Estados Unidos, 06102
        • Aún no reclutando
        • Hartford Healthcare Cancer Institute @ Hartford Hospital
        • Contacto:
          • Andrew Salner, MD
          • Número de teléfono: 860-972-2803
      • Norwalk, Connecticut, Estados Unidos, 06850
        • Reclutamiento
        • Norwalk Hospital
        • Contacto:
          • Linda Vahdat, MD
          • Número de teléfono: 203-845-4811
    • Florida
      • Miami, Florida, Estados Unidos, 33143
        • Reclutamiento
        • Baptist Alliance MCI
        • Contacto:
          • John Diaz, MD
          • Número de teléfono: 786-596-2000
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Reclutamiento
        • Memorial Sloan Kettering Basking Ridge
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
      • Middletown, New Jersey, Estados Unidos, 07748
        • Reclutamiento
        • Memorial Sloan Kettering Monmouth
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
      • Montvale, New Jersey, Estados Unidos, 07645
        • Reclutamiento
        • Memorial Sloan Kettering Bergen
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
    • New York
      • Brooklyn, New York, Estados Unidos, 11203
        • Reclutamiento
        • Kings County Hopsital Center
        • Contacto:
          • Jason Gonsky, MD
          • Número de teléfono: 718-245-2847
      • Commack, New York, Estados Unidos, 11725
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Commack
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
      • Harrison, New York, Estados Unidos, 10604
        • Reclutamiento
        • Memorial Sloan Kettering Westchester
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
      • Jamaica, New York, Estados Unidos, 11432
        • Reclutamiento
        • Queens Cancer Center of Queens Hospital
        • Contacto:
          • Debra Ferman, MD
          • Número de teléfono: 718-579-6021
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
        • Contacto:
          • Zsofia Stadler, MD
          • Número de teléfono: 646-888-4039
        • Investigador principal:
          • David Solit, MD
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Metropolitan Hospital Center
        • Contacto:
          • Anitha Srinivasan, MD
          • Número de teléfono: 212-423-6262
      • New York, New York, Estados Unidos, 10035
        • Reclutamiento
        • Ralph Lauren Center for Cancer Care and Prevention
        • Contacto:
          • Lewis P. Kampel, MD
          • Número de teléfono: 646-422-4474
      • Richmond Hill, New York, Estados Unidos, 11418
        • Reclutamiento
        • Medisys Health Network (Data Collection Only)
        • Contacto:
          • Rosa Nouvini, MD
          • Número de teléfono: 718-206-6000
      • The Bronx, New York, Estados Unidos, 10451
        • Reclutamiento
        • NYC Health & Hospitals /Lincoln Medical Center
        • Contacto:
          • Monica Reddy Muppidi, MD
          • Número de teléfono: 718-579-4977
        • Investigador principal:
          • Monica Reddy Muppidi, MD
      • Uniondale, New York, Estados Unidos, 11553
        • Reclutamiento
        • Memorial Sloan Kettering Nassau
        • Contacto:
          • David Solit, MD
          • Número de teléfono: 646-888-2641
    • Pennsylvania
      • Allentown, Pennsylvania, Estados Unidos, 18103
        • Reclutamiento
        • Lehigh Valley Health Network
        • Contacto:
          • Suresh Nair, MD
          • Número de teléfono: 610-402-7880

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients with solid or hematologic cancers who may be and considered potential candidates for a therapeutic protocol will be recruited to Part A of this study. Enrollment to therapeutic clinical trials will not be contingent on enrollment in this protocol.

Part B: Research Collection Cohort Patients potentially appropriate will be identified by their treating physician in each participating Disease Management Team.

Descripción

Inclusion Criteria:

Part A:

  • Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
  • Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
  • Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.

Part B:

  • Patients must be successfully registered to Part A of MSKCC IRB# 12-245
  • Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
  • Patient must have successfully consented to Part A of this study.

Part D:

  • Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion Criteria:

All Parts:

  • Unwilling or unable to provide informed consent.

Part C:

  • All patients consenting to Part A are eligible to consent to 12-245, Part C. Most patients will be eligible to receive clinical germline testing with return of results to the patient/health care providers. However, several exclusion criteria apply and are outlined below

    1. Solid tumor patients: Secondary germline analysis using BAM files generated for MSK-IMPACT testing is not an option for patients with solid tumors and an acute or chronic hematologic neoplasm that would preclude the use of blood or saliva as a source of germline DNA. Such patient may be eligible for primary germline testing using a non-blood source of germline DNA as per standard clinical guidelines. Solid tumor patients who have had an allogenic bone marrow/stem cell transplant will only be considered eligible for germline testing under Part C if a sample adequate for germline testing had previously been collected prior to allogenic bone marrow/stem cell transplant.
    2. Hematologic cancer patients: For patients with a hematopoietic neoplasm, germline testing may be an option under Part C using nail clippings or another non-blood source of DNA as per standard clinical practice. For patients who have had an allogenic bone marrow/stem cell transplant, clinical germline testing will only be considered under Part C if a sample adequate for germline testing had previously been collected prior to Allogenic bone marrow/stem cell transplant.

Part D

  • Exclusion criteria are same as those for Part C outlined above.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Pts with solid tumors

Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.

Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.

Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").

Part D: Germline Profiling for Individuals at Elevated Cancer Risk

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
frequency of "actionable" oncogenic mutations
Periodo de tiempo: 1 year

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.
Periodo de tiempo: 1 year

The Bioinformatics Core will assist in interpreting data generated by next-generation sequencing techniques such as WES and WGS.

1 year
interrogate the mechanisms
Periodo de tiempo: 1 year

underlying response and resistance (de-novo and acquired) to targeted therapy. The research assay(s) used to accomplish this will vary based on the clinical setting and tissue available and may include Sanger, Sequenom, MiSeq, exon-capture (ie: IMPACT), whole exome, and whole genome sequencing.

1 year
To explore the genetic mechanisms of tumorigenesis
Periodo de tiempo: 2

in a subset of specimens with no identifiable culpritic genomic alterations on highly-multiplexed next-generation sequencing (i.e.: IMPACT testing) by using even more comprehensive investigational profiling techniques such as whole exome sequencing, whole genome sequencing or RNA sequencing

2

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: David Solit, MD, Memorial Sloan Kettering Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de enero de 2013

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de enero de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de enero de 2013

Primero enviado que cumplió con los criterios de control de calidad

21 de enero de 2013

Publicado por primera vez (Estimado)

24 de enero de 2013

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir